Mycolic acid-containing bacteria activate heterologous secondary metabolite expression in Streptomyces lividans
The Journal of Antibiotics advance online publication, April 1 2015. doi:10.1038/ja.2015.31
Authors: Hiroyasu Onaka, Taro Ozaki, Yukiko Mori, Masumi Izawa, Shohei Hayashi & Shumpei Asamizu
Synthesis and antibacterial evaluation of some teicoplanin pseudoaglycon derivatives containing alkyl- and arylthiosubstituted maleimides
The Journal of Antibiotics advance online publication, April 1 2015. doi:10.1038/ja.2015.33
Authors: Magdolna Csávás, Adrienn Miskovics, Zsolt Szűcs, Erzsébet Rőth, Zsolt L Nagy, Ilona Bereczki, Mihály Herczeg, Gyula Batta, Éva Nemes-Nikodém, Eszter Ostorházi, Ferenc Rozgonyi, Anikó Borbás & Pál Herczegh
In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa
The Journal of Antibiotics advance online publication, March 25 2015. doi:10.1038/ja.2015.27
Authors: Xiuzhen Di, Rui Wang, Bin Liu, Xin Zhang, Wentao Ni, Jin Wang, Beibei Liang, Yun Cai & Youning Liu
Induced production of BE-31405 by co-culturing of Talaromyces siamensis FKA-61 with a variety of fungal strains
The Journal of Antibiotics advance online publication, March 25 2015. doi:10.1038/ja.2015.28
Authors: Kenichi Nonaka, Masato Iwatsuki, Syunsuke Horiuchi, Kazuro Shiomi, Satoshi Ōmura & Rokuro Masuma
Bioconversion of FR901459, a novel derivative of cyclosporin A, by Lentzea sp. 7887
The Journal of Antibiotics advance online publication, March 18 2015. doi:10.1038/ja.2015.19
Authors: Satoshi Sasamura, Motoo Kobayashi, Hideyuki Muramatsu, Seiji Yoshimura, Takayoshi Kinoshita, Hidenori Ohki, Kazuki Okada, Yoko Deai, Yukiko Yamagishi & Michizane Hashimoto
Nonomuraea indica sp. nov., novel actinomycetes isolated from lime-stone open pit mine, India
The Journal of Antibiotics advance online publication, March 18 2015. doi:10.1038/ja.2015.24
Authors: Syed Raziuddin Quadri, Xin-Peng Tian, Jing Zhang, Jie Li, Guo-Xing Nie, Shu-Kun Tang, Jamal Al Ruwaili, Dayanand Agsar, Wen-Jun Li & Syed G Dastager
Rectal chlamydia diagnoses have been increasing among MSM and may also rise among women as anal sex rates increase among heterosexuals. However, there is growing concern about treatment for rectal chlamydia with treatment failures of up to 22% being reported. This article addresses factors that may be contributing to treatment failure for rectal chlamydia, including the pharmacokinetic properties of azithromycin and doxycycline in rectal tissue, the ability of chlamydia to transform into a persistent state that is less responsive to antimicrobial therapy, the impact of the rectal microbiome on chlamydia, heterotypic resistance, failure to detect cases of lymphogranuloma venereum and the performance of screening tests. If we are to reduce the burden of genital chlamydia, treatment for rectal chlamydia must be efficacious. This highlights the need for randomized controlled trial evidence comparing azithromycin with doxycycline for the treatment of rectal chlamydia.
